Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy

Pruneri, Giancarlo; Galli, Stefano; Rossi, Roberta; Roncalli, Massimo; Coggi, Guido; Ferrari, A.; Simonato, A.; Siccardi, Antonio G.; Carboni, Nadia; Buffa, Roberto

doi:10.1002/(sici)1097-0045(19980201)34:2<113::aid-pros5>3.0.co;2-l

Cited by 46 publications

(24 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to this classification, 11 out of 50 (22%) patients were classified as Cg-A positive, which is similar to the finding of NE cell differentiation in 25% of prostate cancers reported by Casella et al (15). Prueri et al (17) reported that the number of Cg A-positive cells was significantly greater in the group with Gleason scores of six or over. However, we found no significant differences in age, pre-biopsy serum PSA value, Gleason score, EOD grade, T stage or N stage between the Cg A-positive and Cg A-negative groups.…”

Section: Discussionsupporting

confidence: 87%

Is neuroendocrine cell differentiation detected using chromogranin A from patients with bone metastatic prostate cancer a prognostic factor for outcome?

Yamada

Nakamura²,

Aoki³

et al. 2006

Oncol Rep

View full text Add to dashboard Cite

Abstract.We evaluated the usefulness of overexpression of neuroendrocrine (NE) cell differentiation determined by immunohistochemical staining for chromogranin A (Cg A) in diagnostic needle biopsy specimens of bone metastatic prostate cancers. A total of 50 patients diagnosed as having bone metastatic prostate cancer were studied. The period of observation was between 6.9 and 79.4 months (median 48.7 months). Cg A was detected by immunostaining using the labeled streptavidin biotin method. Cg A-positivity was defined as the presence of immunostained cells in 10% or more of the tumor. All statistical analyses were carried out using the Statistical Package for Social Sciences Software, version 10.0 for Windows. Eleven patients (22%) were classified into the Cg A-positive group. There were no significant differences in clinical data between the Cg Apositive and Cg A-negative groups. The 5-year causespecific survival rate was 34.1% for the Cg A-positive group and 55.2% for the Cg A-negative group (p=0.3763). The 3-year non-recurrence rate was 9.1% for the Cg A-positive group and 35.9% for the Cg A-negative group, and this difference was significant (p=0.0253). The 3-year causespecific survival rates after recurrence were 38.4% and 42.3% respectively (p=0.8125). We consider that NE cell differentiation of the primary tumor in cases of bone metastatic prostate cancer is not a prognostic factor for outcome.

show abstract

Section: Discussionsupporting

confidence: 87%

Is neuroendocrine cell differentiation detected using chromogranin A from patients with bone metastatic prostate cancer a prognostic factor for outcome?

Yamada

Nakamura²,

Aoki³

et al. 2006

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Cancer Res 2007; 67: (8). April 15, 2007 the constitutively active, FLAG-tagged caCqr were derived (Fig.…”

Section: Cancer Researchmentioning

confidence: 99%

“…However, their numbers increase in neoplastic growths, and their prevalence correlates with tumor size and progression to hormone-resistant states (4)(5)(6)(7)(8)(9), suggesting that they may play a role in advancing the disease. A large number of clinical studies have shown that prostatic neuroendocrine-like cells and their associated markers serve as prognostic indicators of poor patient survival (10)(11)(12)(13)(14)(15)(16), providing further support for a functional link between neuroendocrine-like cells and tumor progression.…”

Section: Introductionmentioning

confidence: 99%

Androgen-Independent Growth and Tumorigenesis of Prostate Cancer Cells Are Enhanced by the Presence of PKA-Differentiated Neuroendocrine Cells

et al. 2007

View full text Add to dashboard Cite

The neuroendocrine status of prostatic adenocarcinomas is considered a prognostic indicator for development of aggressive, androgen-independent disease. Neuroendocrine-like cells are thought to function by providing growth and survival signals to surrounding tumor cells, particularly following androgen ablation therapy. To test this hypothesis directly, LNCaP cells were engineered to inducibly express a constitutively activated form of the cyclic AMP-dependent protein kinase A catalytic subunit (caPKA), which was previously found upon transient transfection to be sufficient for acquisition of neuroendocrine-like characteristics and loss of mitotic activity. Clonal cells that inducibly expressed caPKA enhanced the growth of prostate tumor cells in anchoragedependent and anchorage-independent in vitro assays as well as the growth of prostate tumor xenografts in vivo, with the greatest effects seen under conditions of androgen deprivation. These results suggest that neuroendocrine-like cells of prostatic tumors have the potential to enhance androgenindependent tumor growth in a paracrine manner, thereby contributing to progression of the disease. [Cancer Res 2007;67(8):3663-72]

show abstract

“…For example, Noordzij et al 6 did not detect any association between NE differentiation and tumor grade, but others have found the opposite. 7,8 In two studies CgA expression was associated with an advanced stage of disease, 9,10 whereas other studies did not confirm these relations with any clinical or pathologic stage. 7,8 Immunocytochemical studies recently have shown that NE cells of the prostate do not contain androgen receptors and therefore have to be considered androgen independent.…”

mentioning

confidence: 98%

Circulating neuroendocrine markers in patients with prostate carcinoma

Berruti

Dogliotti

Mosca

et al. 2000

Cancer

115

100

View full text Add to dashboard Cite

Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy

Cited by 46 publications

References 38 publications

Is neuroendocrine cell differentiation detected using chromogranin A from patients with bone metastatic prostate cancer a prognostic factor for outcome?

Is neuroendocrine cell differentiation detected using chromogranin A from patients with bone metastatic prostate cancer a prognostic factor for outcome?

Androgen-Independent Growth and Tumorigenesis of Prostate Cancer Cells Are Enhanced by the Presence of PKA-Differentiated Neuroendocrine Cells

Circulating neuroendocrine markers in patients with prostate carcinoma

Contact Info

Product

Resources

About